People’s willingness to have a coronavirus vaccine is increasing across the world, according to a new report on attitudes towards COVID-19 vaccines.
Imperial is focusing its RNA vaccine technology to target SARS-CoV-2 mutations, boosters and thermostability rather than an immediate efficacy trial.
Imperial researchers will lead a new consortium of UK virologists to study the effects of emerging mutations in SARS-CoV-2.
The new SARS-CoV-2 variant is growing rapidly, is more transmissible than other variants, and affecting a greater proportion of under 20s.